Cargando…

Experiences with Next-Generation Sequencing in Relapsed Acute Myeloid Leukemia: A Patient Case Series

Detalles Bibliográficos
Autores principales:	Flach, Johanna, Shumilov, Evgenii, Porret, Naomi, Shakhanova, Inna, Legros, Myriam, Kronig, Marie-Noëlle, Joncourt, Raphael, Bacher, Ulrike, Pabst, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Università Cattolica del Sacro Cuore 2020
Materias:	Scientific Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485469/ https://www.ncbi.nlm.nih.gov/pubmed/32952979 http://dx.doi.org/10.4084/MJHID.2020.068

Ejemplares similares

Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use
por: Bacher, Ulrike, et al.
Publicado: (2018)

Feasibility and efficacy of salvage allogeneic stem cell transplantation in AML patients relapsing after autologous stem cell transplantation
por: Shumilov, Evgenii, et al.
Publicado: (2021)

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
por: Sanoyan, Dilara Akhoundova, et al.
Publicado: (2023)

Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology
por: Shumilov, Evgenii, et al.
Publicado: (2022)

Experiences with Glofitamab Administration following CAR T Therapy in Patients with Relapsed Mantle Cell Lymphoma
por: Heini, Alexander D., et al.
Publicado: (2022)

Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients
por: Nydegger, Anna, et al.
Publicado: (2021)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
por: Rentsch, Vera, et al.
Publicado: (2022)

sBCMA Plasma Level Dynamics and Anti-BCMA CAR-T-Cell Treatment in Relapsed Multiple Myeloma
por: Seipel, Katja, et al.
Publicado: (2022)

Correlation of plasma cell assessment by phenotypic methods and molecular profiles by NGS in patients with plasma cell dyscrasias
por: Rebmann Chigrinova, Ekaterina, et al.
Publicado: (2022)

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients
por: Shumilov, Evgenyi, et al.
Publicado: (2019)

Clonal Hematopoiesis after Autologous Stem Cell Transplantation Does Not Confer Adverse Prognosis in Patients with AML
por: Heini, Alexander D., et al.
Publicado: (2021)

Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome
por: Lakomy, Tim, et al.
Publicado: (2023)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2019)

When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis
por: Bonadies, Nicolas, et al.
Publicado: (2021)

HSP90 Inhibitor PU-H71 in Combination with BH3-Mimetics in the Treatment of Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2023)

NGS Evaluation of a Bernese Cohort of Unexplained Erythrocytosis Patients
por: Jalowiec, Katarzyna Aleksandra, et al.
Publicado: (2021)

A case of CIDP concurrent with MGUS IgG kappa responsive to autologous stem cell transplantation
por: Colucci, Giuseppe, et al.
Publicado: (2020)

Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma
por: Bühler, Selina, et al.
Publicado: (2023)

A Real-World Study on Clofarabine and Cytarabine Combination in Patients with Relapsed/Refractory Acute Myeloid Leukemia
por: Crobu, Valeria, et al.
Publicado: (2019)

CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma
por: Wittibschlager, Valerie, et al.
Publicado: (2023)

Correlation of Peripheral Chimeric Antigen Receptor T-cell (CAR-T Cell) mRNA Expression Levels with Toxicities and Outcomes in Patients with Diffuse Large B-cell Lymphoma
por: Messerli, Christian, et al.
Publicado: (2023)

CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement
por: Shumilov, Evgenii, et al.
Publicado: (2023)

Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2022)

(2R,3S)-Dihydroxybutanoic Acid Synthesis as a Novel Metabolic Function of Mutant Isocitrate Dehydrogenase 1 and 2 in Acute Myeloid Leukemia
por: Idle, Jeffrey R., et al.
Publicado: (2020)

Systemic mastocytosis with an associated hematological neoplasms: One or two entities?
por: Njue, Linet, et al.
Publicado: (2020)

Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

Treating Relapsed/Refractory Acute Myeloid Leukemia with Chidamide, Fludarabine, Cytarabine and Granulocyte-Colony Stimulating Factor with Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation
por: Yao, Wen, et al.
Publicado: (2022)

Myeloid Sarcoma Presenting as Brain Tumor in Pediatric Acute Myeloid Leukemia Case
por: Solgun, Hüseyin Avni, et al.
Publicado: (2023)

Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsing after Autologous Transplant before Availability of CAR-T Cell Treatment
por: von Matt, Stefanie, et al.
Publicado: (2023)

Myeloid leukemia: are we getting better?()
por: Hamerschlak, Nelson
Publicado: (2015)

JAK2 Unmutated Polycythaemia—Real-World Data of 10 Years from a Tertiary Reference Hospital
por: Jalowiec, Katarzyna Aleksandra, et al.
Publicado: (2022)

Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial
por: Farag, Sarah, et al.
Publicado: (2022)

BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia
por: Seipel, Katja, et al.
Publicado: (2021)

Next-generation Internet
por: Engebretson, J
Publicado: (2002)

What will they think of next?
por: Haas, Laura
Publicado: (2003)

Building the next IT revolution
por: Lloyd, Steve
Publicado: (2003)

Treatment of Relapsed Acute Myeloid Leukemia
por: Thol, Felicitas, et al.
Publicado: (2020)

The Grid - the next generation internet
por: Gimblett, A
Publicado: (2003)

Minimal Residual Disease Diagnostics and Chimerism in the Post-Transplant Period in Acute Myeloid Leukemia
por: Bacher, Ulrike, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0oq014p4evhf9lpou47h0c5s81